The historical rank and industry rank for Allogene Therapeutics's Net Margin % or its related term are showing as below:
ALLO'
s Net Margin % Range Over the Past 10 Years
Min: -344489.47 Med: -218214.1 Max: -159.57
Current: -344489.47
ALLO's Net Margin % is ranked worse than 98.93% of 1029
companies
in the Biotechnology industry
Industry Median: -162.58
vs ALLO: -344489.47
Allogene Therapeutics Net Margin % Historical Data
The historical data trend for Allogene Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allogene Therapeutics's Net Margin %
For the Biotechnology subindustry, Allogene Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's Net Margin % falls into.
Allogene Therapeutics Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Allogene Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (NAS:ALLO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Allogene Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics (Allogene Therapeutics) Business Description
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 